8-KOther EventsExhibits & Filings

BIOGEN INC. 8-K Report, Corporate Update (Apr 30, 2020)

Filed April 30, 2020For Securities:BIIB

Summary

Biogen Inc. (BIIB) announced on April 30, 2020, the completion of a $3.0 billion senior notes offering. This offering consists of $1.5 billion in 2.250% Senior Notes due 2030 and $1.5 billion in 3.150% Senior Notes due 2050. The company plans to use the net proceeds from this issuance to redeem $1.5 billion of its outstanding 2.90% Senior Notes due September 2020, fund stock repurchases under its existing plans, and for general corporate purposes including working capital. This significant debt financing indicates Biogen's strategy to refinance existing debt with longer-term notes at potentially lower interest rates and to manage its capital structure. The redemption of the 2020 notes suggests a proactive approach to debt maturity management and cost optimization. Investors should note the details of the new notes, including their senior unsecured status, redemption provisions, and change-of-control clauses, as well as the allocation of proceeds for stock buybacks, which could impact share price.

Key Highlights

  • 1Biogen Inc. completed a $3.0 billion senior notes offering on April 30, 2020.
  • 2The offering comprises two tranches: $1.5 billion of 2.250% Senior Notes due May 1, 2030, and $1.5 billion of 3.150% Senior Notes due May 1, 2050.
  • 3Proceeds will be used to redeem $1.5 billion of outstanding 2.90% Senior Notes due September 2020.
  • 4A portion of the proceeds will fund Biogen's common stock repurchase programs.
  • 5The remaining proceeds are allocated for working capital and other general corporate purposes.
  • 6The notes are senior unsecured obligations of Biogen.
  • 7The offering was conducted under an automatic shelf registration statement filed on April 24, 2020.

Frequently Asked Questions

The primary purposes are to redeem $1.5 billion of existing 2.90% Senior Notes due September 15, 2020, to fund stock repurchases under Biogen's existing plans, and to provide for working capital and other general corporate purposes.

The new notes consist of $1.5 billion of 2.250% Senior Notes due May 1, 2030, and $1.5 billion of 3.150% Senior Notes due May 1, 2050.

This issuance refinances a portion of Biogen's debt, replacing shorter-term debt with longer-term obligations. It also provides capital for shareholder returns through stock buybacks and supports ongoing operations. The new notes are senior unsecured obligations, meaning they rank equally with other unsecured and unsubordinated debt.

Yes, the notes can be redeemed at Biogen's option. Additionally, there is a change-of-control provision that may require Biogen to offer to repurchase the notes at 101% of the principal amount if certain circumstances related to a change of control occur.